Increasing incidence of dermatosis at the background of reduced immunological response to the impact of exo- and endogenous pathogenic agents dictate the necessity of a more profound research of the problem. In addition, antibiotic and immunosuppressive therapy led to activation of saprobic and conventionally pathogenic microflora which is believed to play a prevalent role in the development of dermatosis and, in particular, psoriasis.

Today, platelet-rich plasma is most frequently used in dermatology as an additional method of treatment for different types of alopecia, post-acne, acne, angioneurosis, acute and chronic ulcers with different etiology (diabetic, venous, traumatic, etc.), secondary hyperpigmentation spots and various cosmetic skin defects.

The blood plasma is able to provide a large amount of growth factors and various proteins that can stimulate the healing process. Plasma therapy accelerates neovascularization, increases blood supply and supply of nutrients necessary for cell regeneration in damaged tissue. Plasma therapy stimulates the proliferation and differentiation of cells involved in the healing process.

According to some authors, the prevalence of onychomycosis in the general population is 10- 20%, it increases with age and is 31% in people aged over 60 years. This affects the quality of life of patients, the risk of infecting contact persons and social adaptation. The treatment of such patients is long-term and not always effective due to concomitant pathology, which should be taken into consideration and corrected by the complex therapy for patients with onychomycosis.

In the view of recent events in the world, namely the pandemic, the problem of hair loss in people who have suffered a Coronavirus infection is becoming increasingly frequent in the practice of dermatologists. The connection between the hair loss and COVID-19 still needs to be investigated.

In the problem of eczema, the vascular component of its pathogenesis is of the topical importance. It has been established that the immune conflict condition is accompanied by the intensification of production or release of a wide range of substances exhibiting vasoactive effect as well. In such cases, one can consider changes in the vascular wall with subsequent activation of the thrombocytic-vascular and coagulation links of the haemostasis. Disagreement of literature data, as well as the need for therapeutic correction of haemocoagulation disorders in eczema patients necessitated further in-depth study of this process.